Pay in 4 interest-free payments of $6.04 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
doi: 10.3389/fped.2019.00059 502 NishikaiMTomomatsuSHankinsRWTakagiSMiyachiKKosakaSet al
1 The LEADER trial (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome ResultsA Long-Term Evaluation), a large double-blind, placebo-controlled trial, recently demonstrated that liraglutide added to standard therapy for a relatively short period of time (3.5-5 years) had a significant reduction in cardiovas-cular events and mortality compared to placebo in high-risk patients (hazard ratio [HR], 0.87
Another example would be in somebody where maybe theyre being told to eat more protein, and maybe theyre also on a proton pump inhibitor
If people will just hear the headline and then run with it
R., Asbaghi, O., Naeini, F., Afsharfar, M., Mirzadeh, E., & Naserizadeh, S
US$ 25.44
US$ 26.59
US$ 24.95
US$ 22.87
US$ 28.98
